The study explores whether Prolia/Xgeva (denosumab), a widely used therapy for osteoporosis and bone tumors, can regenerate ...

On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)U.S. FDA BLA submission for accelerated approval planned ...

SARMs can lower natural testosterone levels, so a recovery phase may be needed after the cycle. For LGD-4033, the effect on ...

Oxford Nanoimaging (ONI), a leader in super-resolution microscopy, is revolutionizing lipid nanoparticle (LNP) analysis with ...

Precious metals are not merely ornaments; they are also important components of pharmaceuticals, like the antitumor drug ...

First VISTA Inhibitor Drug Approval By 2028 Says Kuick Research In New Research Publication. Delhi, April 02, 2025 (GLOBE NEWSWIRE) -- Global VISTA Inhibitor Clini ...

Sapio Sciences has integrated the NVIDIA BioNeMo platform into its lab informatics platform, enhancing AI-driven ...

Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed ...

Otsuka Pharmaceutical Development & Commercialization Inc. filed its BLA with the U.S. FDA for sibeprenlimab to treat immunoglobulin A nephropathy (IgAN). The company’s first BLA, sibeprenlimab is a ...